Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call
(Thomson Reuters ONE) -
SAN DIEGO, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that the Company's second quarter
2016 financial results will be released on Thursday, August 4, 2016 at 4:01 p.m.
Eastern Time. Company management will host a conference call on Thursday,
August 4, 2016, at 4:30 p.m. Eastern Time to discuss the financial results and
other recent corporate highlights.
To participate by telephone, please dial (855) 780-7196 (Domestic) or (631)
485-4867 (International). The conference ID number is 57715600. The live audio
webcast can be accessed via the Investor Relations' section of the Company's
website at www.apricusbio.com. Please log in approximately 5-10 minutes before
the event to ensure a timely connection. The archived webcast will remain
available for 30 days following the live call.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros(®), for the treatment of erectile dysfunction, is approved in Europe and
Canada and is being commercialized in several countries in Europe. In September
2015, Apricus in-licensed the U.S. development and commercialization rights for
Vitaros from Allergan. Apricus' marketing partners for Vitaros include Recordati
Ireland Ltd. (Recordati S.p.A.), Ferring International Center S.A. (Ferring
Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis
Pharmaceuticals Ltd. Apricus currently has one active product candidate,
RayVa((TM)), its product candidate for the treatment of the circulatory disorder
Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros(®) is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
CONTACT:
Institutional / Retail Investors:
Matthew Beck
mbeck(at)troutgroup.com
The Trout Group LLC
(646) 378-2933
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
[HUG#2032140]
Unternehmensinformation / Kurzprofil:
Datum: 01.08.2016 - 13:00 Uhr
Sprache: Deutsch
News-ID 486541
Anzahl Zeichen: 2949
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 230 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
